First Patient with HSCT-TMA Completes Nomacopan Treatment in Phase 3 Trial
Photo courtesy of Towfiqu Barbhuiya on Unsplash

First Patient with HSCT-TMA Completes Nomacopan Treatment in Phase 3 Trial

  On July 7, 2022, biotechnology company Akari Therapeutics, Plc ("Akari") shared via news release that the first patient in its clinical trial has completed their course of treatment. Within…

Continue Reading First Patient with HSCT-TMA Completes Nomacopan Treatment in Phase 3 Trial
First CAR T-Cell Therapy for Multiple Myeloma Cleared for Use in Japan
source: pixabay.com

First CAR T-Cell Therapy for Multiple Myeloma Cleared for Use in Japan

According to a press release from the pharmaceutical company Bristol Myers Squibb, the company's CAR T-Cell therapy idecabtagene vicleucel (marketed as Abecma) has been approved by the Japanese Ministry of…

Continue Reading First CAR T-Cell Therapy for Multiple Myeloma Cleared for Use in Japan
EC Approves Inrebic for Splenomegaly with Myelofibrosis 
qimono / Pixabay

EC Approves Inrebic for Splenomegaly with Myelofibrosis 

On February 8, 2021, global biopharmaceutical company Bristol Myers Squibb shared that the European Commission (EC) approved a Marketing Authorization Application (MAA) for Inrebic (fedratinib). For around 10 years, there…

Continue Reading EC Approves Inrebic for Splenomegaly with Myelofibrosis 
NMPA Grants Conditional Approval to XOSPATA for FLT3mut+ AML
rawpixel / Pixabay

NMPA Grants Conditional Approval to XOSPATA for FLT3mut+ AML

  In an early February press release, pharmaceutical company Astellas Pharma Inc. ("Astellas") shared that XOSPATA (gilteritinib) was given conditional approval in China for the treatment of patients with FLT3-mutated…

Continue Reading NMPA Grants Conditional Approval to XOSPATA for FLT3mut+ AML
Phase 1b Data Shows Magrolimab Clinical Response for AML
source: pixabay.com

Phase 1b Data Shows Magrolimab Clinical Response for AML

In early December 2020, biopharmaceutical company Gilead Sciences, Inc. ("Gilead") shared updated results from a Phase 1b clinical trial evaluating magrolimab for patients with treatment-naïve acute myeloid leukemia (AML). Generally,…

Continue Reading Phase 1b Data Shows Magrolimab Clinical Response for AML

New Investigative Therapy for Myelofibrosis Patients with Severe Thrombocytopenia is Making Headway

CTI BioPharma has just announced that they are submitting a NDA for Pacritinib as a new option for myelofibrosis patients who are facing severe thrombocytopenia. The thrombocytopenia is a result…

Continue Reading New Investigative Therapy for Myelofibrosis Patients with Severe Thrombocytopenia is Making Headway
Study: Felty’s Syndrome Presents Differently in Pediatric Patients
source: pixabay.com

Study: Felty’s Syndrome Presents Differently in Pediatric Patients

According to a study published in BMC Pediatrics, the rare disease known as Felty's syndrome is primarily known to affects adults between the ages of 50 and 70, but on very rare…

Continue Reading Study: Felty’s Syndrome Presents Differently in Pediatric Patients
Rivaroxaban Lowers Risk of Venous Thromboembolism for Orthopedic Surgeries as Compared to Heparin
source: pixabay.com

Rivaroxaban Lowers Risk of Venous Thromboembolism for Orthopedic Surgeries as Compared to Heparin

  According to a news release from the American College of Cardiology, rivaroxaban is more effective than enoxaprin (heparin) in preventing blood clots or low platelet counts in patients after…

Continue Reading Rivaroxaban Lowers Risk of Venous Thromboembolism for Orthopedic Surgeries as Compared to Heparin
XPOVIO Being Evaluated for Treatment of Diffuse Large B-Cell Lymphoma
Source: https://pixabay.com/en/white-blood-cell-cell-blood-cell-543471/

XPOVIO Being Evaluated for Treatment of Diffuse Large B-Cell Lymphoma

Karyopharm, a pharmaceutical company based in Newton, Massachusetts, has submitted a New Drug Application to the FDA for their drug XPOVIO, which is meant for the treatment of diffuse large…

Continue Reading XPOVIO Being Evaluated for Treatment of Diffuse Large B-Cell Lymphoma
Experimental Treatment for Immune Thrombocytopenia Begins Trials in China
kalhh / Pixabay

Experimental Treatment for Immune Thrombocytopenia Begins Trials in China

According to a story from uk.finance.yahoo.com, the company Hutchison China MediTech Limited ("Chi-Med") has recently kicked off a phase 1 clinical trial. This trial is testing the company's investigational drug…

Continue Reading Experimental Treatment for Immune Thrombocytopenia Begins Trials in China
NIH Grants Funding for Scientist’s Heparin-Induced Thrombocytopenia Biomarker Research
source: pixabay.com

NIH Grants Funding for Scientist’s Heparin-Induced Thrombocytopenia Biomarker Research

According to a publication on EurekAlert, the National Institutes of Health recently awarded Dr. Jason Karnes, PharmD, PhD (and assistant professor in the University of Arizona College of Pharmacy) with…

Continue Reading NIH Grants Funding for Scientist’s Heparin-Induced Thrombocytopenia Biomarker Research